Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Biological Assay × 1 year × Clear all
NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Columbia University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

NCT06716580 2025-12-10

EQUAL

Dana-Farber Cancer Institute

Phase NA Recruiting
1,000 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡